Cooperative Agreement R44CK000578

This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Phase I Small Business Innovation Research (SBIR) project awarded to Multitarga LLC aims to develop an adaptive multi-targeted priming platform, called HostPathEP, to improve the sensitivity and specificity of RNA sequencing for detecting low-abundance pathogen transcripts in complex host-pathogen samples. The $304,995 award, effective June 1, 2025 through May 31, 2026, will fund the development of...

This federal Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), under the "Discovery and Applied Research for Technological Innovations to Improve Human Health" (CFDA 93.286) program, provides $980,779 to the University of Cincinnati to develop a deployable and adaptable plasmonic sensing platform for infectious disease surveillance. The goal is to create a highly sensitive and accurate point-of-need diagnostic system capable of...

This SBIR Phase I grant, awarded by the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (CFDA 47.084) program, provides $305,000 to Novaurum Biosciences Incorporated to develop a novel mammalian cell-based nano-biological coating for implantable medical devices. The goal is to address the critical health and economic burden associated with implant-related infections by creating a biocompatible and antimicrobial coating that can inhibit biofilm formation and...

The federal Project Grant award R43JG000002 from the Centers for Disease Control and Prevention (CDC) Investigations and Technical Assistance program (CFDA 93.283) was awarded to Kephera Diagnostics LLC, a for-profit limited liability company, to develop a two-minute rapid assay platform for point-of-care diagnosis. The $606,500 grant, awarded on September 30, 2024, with a completion date of March 31, 2025, will support the company's research and development efforts to create specialized in...

This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $1,000,000 in funding to Partillion Bioscience Corp to develop advanced workflows utilizing their "nanovial" hydrogel microparticle technology. The goal is to enable ultra high-throughput screening and functional assessment of single B cells and antibody-secreting cells to improve antibody discovery...

The federal Project Grant award R43OD037625, funded by the Department of Health and Human Services' National Institutes of Health (NIH) under the Research Infrastructure Programs (CFDA 93.351), supports the development of an innovative machine vision guided robotic system to automate microinjection procedures for Drosophila melanogaster (fruit fly) embryos. Objective Biotechnology, Inc., a biotechnology spin-out from the University of Minnesota, is pioneering this automated microinjection...

The National Science Foundation (NSF) awarded a $275,000 SBIR Phase I grant under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program to Om Therapeutics Inc. in La Jolla, CA. The goal of this project is to enable the discovery of new medicines at an unprecedented rate by empowering researchers to launch drug discovery programs quickly and cost-effectively. The innovation involves the ability to screen billions of unique small molecules against the entire human proteome in a...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will support the development of a novel universal rapid test for HIV diagnosis. IGE Immunodiagnostics & Therapeutics, LLC, a minority-owned small business, will receive $294,948 to adapt their existing HIV ELISA test into a 5th generation antigen/antibody combination rapid test format. The goal is to create a simple, rapid,...

This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $300,000 to Biotherapeutics, Inc., a biotechnology company located in Blacksburg, Virginia. The funding supports the development of a novel, oral, once-daily, immunoregulatory therapeutic for the treatment of Clostridioides difficile infection (CDI). This first-in-class product candidate aims to provide...

This SBIR Phase I award from the National Science Foundation (NSF) under the NSF Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) provides $273,550 to Biocognon LLC for the development of a combinatorial platform to discover improved molecular recognition components for use in therapeutic and diagnostic antibodies. The project aims to utilize synthetic biology, next-generation DNA sequencing, and computational biology to efficiently generate and screen libraries of antibody...